CHEMED CORP

CHE stock represents shares of Chemed Corporation, a company listed on the New York Stock Exchange. Chemed operates through two main segments: VITAS Healthcare, which provides hospice and palliative care services, and Roto-Rooter, a provider of plumbing and drain cleaning services. Investors tracking CHE are gaining exposure to both healthcare and residential services industries.

Recent performance for CHE can be found by checking the latest price, daily change, and performance chart on this page. Short-term movements may reflect earnings reports, healthcare sector trends, or broader market conditions. Comparing CHE's recent returns to relevant benchmarks and sector peers can help put its performance in context.

Valuation for CHE can be assessed using metrics such as the price-to-earnings ratio, price-to-sales ratio, and enterprise value-to-EBITDA, compared against healthcare and industrial peers. Because Chemed operates in two distinct industries, segment-level analysis may also be useful. Current valuation metrics are available on this page, along with historical comparisons.

CHE may be available for trading in pre-market and after-hours sessions on U.S. exchanges, though liquidity is often lower than during regular trading hours. Extended-hours trades carry additional risks, including wider spreads and higher volatility. Availability depends on the brokerage, and current pre- and post-market quotes should be checked on the page.

Chemed Corporation has a history of paying quarterly dividends to shareholders. The current dividend amount, yield, and payment schedule are displayed in the dividend section of this page. Investors often review CHE's dividend history alongside its payout ratio and free cash flow to assess sustainability.

Key risks for CHE include regulatory changes affecting hospice reimbursement, labor shortages or rising wages in healthcare and plumbing services, and competition in both segments. Litigation, Medicare/Medicaid policy shifts, and broader economic downturns could also impact results. Investors should review Chemed's latest 10-K and 10-Q filings for detailed risk disclosures.